4.61

5.98% 0.26

Galectin Therapeutics Inc (GALT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$4.35

Aprire:

$4.33

Volume 24 ore:

473.10K

Relative Volume:

0.74

Capitalizzazione di mercato:

$464.92M

Reddito:

Utile/perdita netta:

$-26.25M

Rapporto P/E:

-11.25

EPS:

-0.4099

Flusso di cassa netto:

$-20.05M

1 W Prestazione:

+14.68%

1M Prestazione:

+54.44%

6M Prestazione:

+48.23%

1 anno Prestazione:

-1.28%

Intervallo 1D:

$4.33

$4.72

Intervallo di 1 settimana:

$3.91

$4.72

Portata 52W:

$2.025

$7.13

Galectin Therapeutics Inc Stock (GALT) Company Profile

Nome

Galectin Therapeutics Inc

Settore

Healthcare (1074)

Industria

Biotechnology (600)

Telefono

678-620-3186

Indirizzo

4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA

Dipendente

Cinguettio

@galectingalt

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

GALT's Discussions on Twitter

Compare GALT vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GALT Galectin Therapeutics Inc	4.61	360.03M	0	-26.25M	-20.05M	-0.4099
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-17	Ripresa	H.C. Wainwright	Buy
2020-08-13	Reiterato	H.C. Wainwright	Buy
2019-02-13	Iniziato	B. Riley FBR	Buy
2017-12-07	Reiterato	H.C. Wainwright	Buy
2017-11-28	Reiterato	H.C. Wainwright	Buy
2017-10-19	Iniziato	ROTH Capital	Buy
2017-03-30	Aggiornamento	H.C. Wainwright	Neutral → Buy
2016-10-03	Downgrade	FBR & Co.	Outperform → Mkt Perform
2016-09-29	Downgrade	H.C. Wainwright	Buy → Neutral
2016-09-28	Downgrade	ROTH Capital	Buy → Sell
2016-03-28	Ripresa	H.C. Wainwright	Buy
2015-09-21	Iniziato	H.C. Wainwright	Buy
2014-08-01	Downgrade	Aegis Capital	Buy → Hold
2014-07-30	Reiterato	MLV & Co	Buy
2014-07-29	Reiterato	MLV & Co	Buy
2014-04-02	Reiterato	MLV & Co	Buy
2014-02-10	Reiterato	Aegis Capital	Buy
2014-01-09	Reiterato	Aegis Capital	Buy
2013-12-03	Iniziato	MLV & Co	Buy
2013-08-19	Reiterato	Aegis Capital	Buy

Mostra tutto

Galectin Therapeutics Inc Borsa (GALT) Ultime notizie

Aug 20, 2026

Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn

Aug 20, 2026

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn

Aug 20, 2026

Aug 18, 2026

HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat

Aug 18, 2026

Aug 17, 2026

Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn

Aug 17, 2026

Aug 15, 2026

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Aug 15, 2026

Aug 14, 2026

Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat

Aug 14, 2026

Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade

Aug 14, 2026

Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart

Aug 14, 2026

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView

Aug 14, 2026

Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com

Aug 14, 2026

Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative

Aug 14, 2026

Galectin Therapeutics、2026年6月30日決算の結果を発表し、事業状況を更新 - Moomoo

Aug 14, 2026

GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView

Aug 14, 2026

Aug 13, 2026

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat

Aug 13, 2026

Aug 10, 2026

Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 08, 2026